Agents Used in Antiretroviral Therapy
Summary
- Raltegravir is indicated in combination with other antiretroviral agents for treatment of HIV infection in adult patients and pediatric patients weighing ≥ 2 kg[FDA Raltegravir]
- Raltegravir plus emtricitabine/tenofovir DF or emtricitabine/tenofovir AF is a recommended INSTI-based first-line regimen in US and European treatment guidelines[DHHS ART; EACS ART]
- Raltegravir is given orally at a dose of 400 mg twice daily or 1200 mg once daily (using 2 tablets of 600-mg formulation)
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content